Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06772610
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:59.790044+00:00
Published At
2025-01-13T00:00:00+00:00
Record Updated At
2025-01-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["NSCLC", "ALK", "Stage I", "Adjuvant Treatment"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-01-13"
protocolSection.identificationModule.nctId
"NCT06772610"
protocolSection.identificationModule.officialTitle
"The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors"
protocolSection.statusModule.overallStatus
"NOT_YET_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • NSCLC (protocolSection.conditionsModule.conditions)
  • ALK (protocolSection.conditionsModule.conditions)
  • Stage I (protocolSection.conditionsModule.conditions)
  • Adjuvant Treatment (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.